WO1994012178A1 - Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds - Google Patents

Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds Download PDF

Info

Publication number
WO1994012178A1
WO1994012178A1 PCT/US1993/011598 US9311598W WO9412178A1 WO 1994012178 A1 WO1994012178 A1 WO 1994012178A1 US 9311598 W US9311598 W US 9311598W WO 9412178 A1 WO9412178 A1 WO 9412178A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
formula
hydrogen
compound
lower alkyl
Prior art date
Application number
PCT/US1993/011598
Other languages
English (en)
French (fr)
Inventor
Frank C. Barone
Giora Feuerstein
Tian-Li Yue
Paul G. Lysko
Hung-Yuan Cheng
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP94903351A priority Critical patent/EP0671914A1/en
Priority to KR1019950702200A priority patent/KR950703950A/ko
Priority to AU57323/94A priority patent/AU673882B2/en
Priority to JP6513451A priority patent/JPH08503711A/ja
Publication of WO1994012178A1 publication Critical patent/WO1994012178A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a new medical use of, and method of treatment using, the hydroxycarbazole compounds of Formula I, as oxygen radical scavengers, or antioxidants, for protection of vital organs, particularly the central nervous system including the brain, from oxidative damage.
  • the present invention provides a new use for such hydroxycarbazole compounds for making pharmaceutical compositions useful in prevention of organ reperfusion injury including related acute inflammation, particularly neuroprotection, that is, protection of the central nervous system from traumatic and post-traumatic injury associated with stroke, e. g., prevention of stroke and neurotrauma, and reduction of morbidity resulting from the sequelae of stroke.
  • R7-R13 are independently -H or-OH.
  • A is independently H, -OH, or a moiety of Formula II:
  • Rj is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
  • R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
  • R3 is hydrogen or lower alkyl of up to 6 carbon atoms;
  • R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent -CH2-O-;
  • X is a valency bond, -CH2, oxygen or sulfur
  • Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;
  • R5 and R ⁇ are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a - CONH2- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or
  • R5 and R6 together represent methylenedioxy; and pharmaceutically acceptable salts thereof.
  • LPO and oxygen radicals in tissue damage associated with ischemia is further supported by the protective effect of natural and synthetic antioxidants such as vitamin E and the lazaroid U-74500A (Levitt, M.A., Clin. Res. (1991) 39, 265A) or antioxidant enzymes such as superoxide dismutase (SOD) and catalase in diverse ischemic models (for review see Halliwell and Gutteridge, 1989).
  • natural and synthetic antioxidants such as vitamin E and the lazaroid U-74500A (Levitt, M.A., Clin. Res. (1991) 39, 265A) or antioxidant enzymes such as superoxide dismutase (SOD) and catalase in diverse ischemic models (for review see Halliwell and Gutteridge, 1989).
  • the present invention provides a new medical use for the hydroxycarbazole compounds of Formula I as oxygen radical scavengers or antioxidants for protection of vital organs from oxidative damage.
  • the present invention provides a new use for compounds preferably selected from the group consisting essentially of the compounds of Formula I wherein A is the moiety of Formula II wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or RJQ is -OH, most preferably the compound of Formula I wherein A is the moiety of Formula II wherein Rl is - H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is - H, and R7 is -OH, or a pharmaceutically
  • the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma, particularly neuroprotection, that is, prevention of stroke and reduction of morbidity resulting from the sequelae of stroke, in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of a compound selected from the group consisting essentially of the compounds of Formula I, preferably selected from the group consisting essentially of the compounds of Formula I wherein A is the moiety of Formula II wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or R1 Q is -OH, most preferably the compound of Formula I wherein A is the moiety of Formula II wherein Rl is -H, R2 is -H, R3 is -H
  • R ⁇ is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
  • R2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;
  • R3 is hydrogen or lower alkyl of up to 6 carbon atoms
  • R4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R4 together with R5 can represent -CH2-O-;
  • X is a valency bond, -CH2, oxygen or sulfur
  • Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;
  • R5 and R ⁇ are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a - CONH2- group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphinyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R5 and R6 together represent methylenedioxy; and pharmaceutically acceptable salts thereof.
  • This patent further discloses a compound of Formula HI, better known as carvedilol ( 1 -(carbazol-4-yloxy-3- [[2- (o-methoxyphenoxy )ethyl] amino] -2- propanol), having the structure shown in Formula IV:
  • Carvedilol is known to be both a competitive ⁇ - adrenoceptor antagonist and a vasodilator, and is also a calcium channel antagonist at higher concentrations .
  • the vasodilatory actions of carvedilol result primarily from ocj -adrenoceptor blockade, whereas the ⁇ -adrenoceptor blocking activity of the drug prevents reflex tachycardia when used in the treatment of hypertension.
  • These multiple actions of carvedilol are responsible for the antihypertensive efficacy of the drug in animals, particularly in humans, as well as for utility in the treatment of angina and CHF.
  • ischemic organ trauma as in stroke, a high proportion of ischemic organ cells become irreversibly damaged and necrotic, the extent of injury being dependent upon the length of time that the trauma, e.g. the arterial occlusion, persists.
  • the protection of central nervous system neurons from such damage and necrosis during occlusion occurring in stroke and post-traumatic reperfusion is essential to achieving the therapeutic goal of restoration of neurological function; here and throughout this application this property is referred to by the term "neuroprotection" and its synonyms.
  • ⁇ -adrenoceptor antagonists for instance propranolol
  • carbazolyl-(4)-oxypropanolamine compounds of Formula I are effective cardioprotective agents at antihypertensive doses which unexpectedly minimize these consequences.
  • ⁇ -adrenoceptor blocking and vasodilatory properties of carvedilol provides cardioprotection during and after acute myocardial infarction.
  • Some of the compounds of Formula I are known to be metabolites of carvedilol in human and other mammalian (e.g. gerbil) systems.
  • the preferred compounds of the present invention that is, the compounds of Formula I wherein A is the moiety of Formula ⁇ wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or R1 Q is -OH are known to be metabolites of carvedilol.
  • the hydroxycarbazole compounds of Formula I are oxygen radical scavengers.
  • oxygen scavengers the above- described compounds act to inhibit LPO, and further that the hydroxycarbazole compounds of Formula I are surprisingly effective protective agents in generally preventing a wide variety of disease states associated with oxidative tissue damage to the organs due to LPO following ischemic traumas.
  • the compounds of the present invention are especially useful in neuroprotection, that is, prevention of stroke, and reduction of morbidity resulting from the sequelae of stroke.
  • the compounds of Formula I preferably selected from the group consisting essentially of the compounds of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is - H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or RJQ is -OH, most preferably the compound of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and R7 is -OH, exhibit neuroprotection, and are especially useful for protecting cerebral tissue from stroke and neurotrauma as well as for preventing oxidative tissue damage of ischemic human cerebral tissue following occurence of an ischemic event such as stroke or cerebral trauma.
  • chronic administration of these compounds can both reduce the risk of cerebral ischemia or stroke in individuals at risk thereof as well as provide adjunctive therapy by reducing the magnitude of oxidative tissue damage following an ischemic cerebral event. Because hypertensive individuals are at increased risk of stroke, the neuroprotective use of the present compounds at appropriate dosing regimens in combination with antihypertensive therapy significantly reduces the risk of stroke, and the sequelae of stroke in such patients.
  • the compounds of Formula I preferably those selected from the group consisting essentially of the compounds of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or R ⁇ is -OH, most preferably the compound of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and R7 is -OH, are useful for neuroprotection in humans according to the present invention at dosages ranging from about 1-3 mg kg i.v. b.i.d. and 3-30 .mg/kg p.o. b.i.d.
  • the present invention also provides a method of treatment for prevention of oxidative tissue damage to organs afflicted with disease-induced ischemic trauma in mammals comprising internally administering to a mammal, preferably a human, in need thereof an effective amount of a compound selected from the group consisting essentially of the compounds of Formula I, preferably those selected from the group consisting essentially of the compounds of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is -H, and one of R7, R9, or RJQ s -OH, most preferably the compound of Formula I wherein A is the moiety of Formula H wherein Rl is -H, R2 is -H, R3 is -H, R4 is -H, X is O, Ar is phenyl, R5 is ortho -OH, and R6 is
  • compositions of the compounds of Formula I for neuroprotective use according to the present invention may be formulated as solutions or lyophilized powders for parenteral administration.
  • Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation is generally a buffered, isotonic, aqueous solution.
  • suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as ethanol, polyvinyl- pyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • these compounds may be encapsulated, tableted or prepared in a emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, ethanol, and water.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US1993/011598 1992-12-01 1993-12-01 Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds WO1994012178A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP94903351A EP0671914A1 (en) 1992-12-01 1993-12-01 Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
KR1019950702200A KR950703950A (ko) 1992-12-01 1993-12-01 히드록시카르바졸 화합물의 항산화성 신경보호 용도 및 이를 이용한 치료 방법(Antioxidant Neuroprotective Use of, and Method of Treatment Using, Hydroxycarbazole Compounds)
AU57323/94A AU673882B2 (en) 1992-12-01 1993-12-01 Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
JP6513451A JPH08503711A (ja) 1992-12-01 1993-12-01 ヒドロキシカルバゾール化合物の抗酸化神経保護的使用およびそれを使用する治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98392092A 1992-12-01 1992-12-01
US07/983,920 1992-12-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08446792 A-371-Of-International 1995-05-30
US88977497A Continuation 1995-05-30 1997-07-08

Publications (1)

Publication Number Publication Date
WO1994012178A1 true WO1994012178A1 (en) 1994-06-09

Family

ID=25530181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011598 WO1994012178A1 (en) 1992-12-01 1993-12-01 Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds

Country Status (8)

Country Link
EP (1) EP0671914A1 (enrdf_load_stackoverflow)
JP (1) JPH08503711A (enrdf_load_stackoverflow)
KR (1) KR950703950A (enrdf_load_stackoverflow)
CN (1) CN1042795C (enrdf_load_stackoverflow)
AU (1) AU673882B2 (enrdf_load_stackoverflow)
CA (1) CA2150695A1 (enrdf_load_stackoverflow)
WO (1) WO1994012178A1 (enrdf_load_stackoverflow)
ZA (1) ZA938897B (enrdf_load_stackoverflow)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002157A1 (de) * 1996-07-13 1998-01-22 Roche Diagnostics Gmbh Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat
WO1998038985A3 (en) * 1997-03-06 1998-12-23 Boehringer Mannheim Gmbh Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
EP0907318A4 (en) * 1996-04-29 2000-02-02 Smithkline Beecham Corp ANTIOXIDING COMPOUND
EP1242070A4 (en) * 1999-12-27 2003-05-28 Yissum Res Dev Co TREATMENT OF CEREBRAL ISCHEMIC INJURY USING BRAIN-TARGETING ANTIOXIDANT COMPOUNDS

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503067A (en) * 1978-04-13 1985-03-05 Boehringer Mannheim Gmbh Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503067A (en) * 1978-04-13 1985-03-05 Boehringer Mannheim Gmbh Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 118, No. 11, issued 1992, LYSKO et al., "Neuroprotective Effects of Carvedilol a New Antihypertensive, at the N-methyl-D- Aspartate Receptor", see Abstract No. 94036w, Neurosci. Lett. 148(1-2), 34-8. *
CHEMICAL ABSTRACTS, Vol. 118, No. 7, issued 1992, LYSKO et al., "Neuroprotective Effects of Carvedilol a New Antihypertensive Agent, in Cultured Rat Cerebellar Neurons and in Gerbil Global Brain Ischemia", Stroke 23(11), 1630-6. *
See also references of EP0671914A4 *
The Journal of Pharmacology and Experimental Therapeutics, Vol. 263, No. 1, issued 1992 (USA), YUE et al.; "Carvedilol, a New Vasodilator and Beta Adrenoreceptor Antagonist, is an Antioxidant and Free Radical Scavenger", pages 92-98, see the Abstract particularly. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0907318A4 (en) * 1996-04-29 2000-02-02 Smithkline Beecham Corp ANTIOXIDING COMPOUND
WO1998002157A1 (de) * 1996-07-13 1998-01-22 Roche Diagnostics Gmbh Topisch einsetzbare pharmazeutische formulierungen enthaltend als wirkstoff ein carbazolyl-(4)-oxy-propanolamin-derivat
WO1998038985A3 (en) * 1997-03-06 1998-12-23 Boehringer Mannheim Gmbh Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
EP1242070A4 (en) * 1999-12-27 2003-05-28 Yissum Res Dev Co TREATMENT OF CEREBRAL ISCHEMIC INJURY USING BRAIN-TARGETING ANTIOXIDANT COMPOUNDS

Also Published As

Publication number Publication date
CN1098908A (zh) 1995-02-22
JPH08503711A (ja) 1996-04-23
AU673882B2 (en) 1996-11-28
CA2150695A1 (en) 1994-06-09
KR950703950A (ko) 1995-11-17
ZA938897B (en) 1994-08-01
AU5732394A (en) 1994-06-22
EP0671914A4 (enrdf_load_stackoverflow) 1995-10-25
EP0671914A1 (en) 1995-09-20
CN1042795C (zh) 1999-04-07

Similar Documents

Publication Publication Date Title
AU675481B2 (en) Antioxydant cardioprotective use of, and method of treatmentusing, hydroxycarbazole compounds
JP4021507B2 (ja) プロリン含有医薬組成物
JPH07108855B2 (ja) 循環器治療薬として有用な酸化窒素―第一級アミン安定化コンプレックス
US5512572A (en) Anti-ischemic medicament
JP2852608B2 (ja) 口腔乾燥症治療剤
JP2002537258A5 (enrdf_load_stackoverflow)
CA2524034A1 (en) Uses of ion channel modulating compounds
HUE034007T2 (en) Treatment of atrial fibrillation
US20010011099A1 (en) Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
AU673882B2 (en) Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
EP1006793B1 (en) Anti-arrhythmic composition and methods of treatment
US5508308A (en) Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
EP0907318A1 (en) Antioxidant compound
IE900306A1 (en) Agent for use in the prevention, control or reversal of¹hypertension
HU208004B (en) Process for producing ascorbinic acid derivatives and pharmaceutical compositions containing them
GB2189703A (en) Vinpocetine
WO2010058779A1 (ja) ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
JPH0576925B2 (enrdf_load_stackoverflow)
HU211747A9 (en) Drugs containing verapamil and trandolapril
CA1256031A (en) Pharmaceutical compositions containing diltiazem and alfuzosin
US4716177A (en) Tolrestat for inhibition of weight gain
Mayrleitner E047/1
HUP9903498A2 (hu) Kettős nemszelektív béta-adrenoceptor és alfa1-adrenoceptor antagonisták alkalmazása stressz-aktivált proteinkinázok gátlására szolgáló gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1995 446792

Country of ref document: US

Date of ref document: 19950530

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2150695

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994903351

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994903351

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1994903351

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994903351

Country of ref document: EP